MNG Laboratories is dedicated to leveraging the latest sequencing technology to remain a leader in neurogenetic diagnostics. This cutting-edge technology is utilized in the sequencing of numerous tests in our growing portfolio.
Massively parallel sequencing, more commonly known as Next-Generation Sequencing (NGS), is a technique that allows for the fast, ultra-high throughput, and scalable sequencing of nucleic acids in biological systems. MNG Laboratories’ sequencing platform utilizes short-read sequencing by synthesis (SBS) chemistry to rapidly and accurately sequence DNA and RNA. Significant advancements in sequencing equipment has greatly expanded the opportunity to provide a fast and accurate diagnosis for patients with genetic conditions.
Capillary Electrophoresis (CE) is a technique that uses an electric field to separate molecules of DNA of different sizes. This method is deployed for Sanger Sequencing, repeat expansion sizing, and deletion/duplication analysis using Multiplex Ligation-dependent Probe Amplification (MLPA).
Dr. Keith Hyland, PhD, runs the Neurochemistry/Metabolic department at MNG Laboratories and is a globally recognized expert in the field of inherited metabolic disease and test method development. Dr. Hyland is well known for his expertise in neurotransmitter disorders and has twice received the annual award of the Society for the Study of Inborn Errors of Metabolism (SSIEM). He has over 150 peer reviewed publications, book chapters, and invited reviews, and has held multiple research grants. Many inherited disorders that affect neurotransmitter metabolism do not lead to biomarker accumulation in peripheral fluids. The Neurochemistry/Metabolic department at MNG therefore provides a comprehensive menu of tests that examine diagnostic analytes in cerebrospinal fluid (CSF). These tests examine the pathways involving serotonin, the catecholamines, gamma aminobutyric acid (GABA), pyridoxine, folic acid, amino acids, and purines. In addition, we analyze neopterin as a marker for immune system stimulation and have biomarkers that indicate the presence of alpha aminoadipic semialdehyde dehydrogenase deficiency, the disorder that leads to pyridoxine responsive seizures.